LEADER 04066nam 22005535 450 001 9910254674503321 005 20200705042227.0 010 $a3-319-26464-8 024 7 $a10.1007/978-3-319-26464-6 035 $a(CKB)3710000000596524 035 $a(EBL)4398739 035 $a(SSID)ssj0001656268 035 $a(PQKBManifestationID)16437388 035 $a(PQKBTitleCode)TC0001656268 035 $a(PQKBWorkID)14984943 035 $a(PQKB)10738903 035 $a(DE-He213)978-3-319-26464-6 035 $a(MiAaPQ)EBC4398739 035 $a(EXLCZ)993710000000596524 100 $a20160208d2016 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aClinical Trials of Antidepressants $eHow Changing the Model Can Uncover New, More Effective Molecules /$fby Martin M. Katz 205 $a1st ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016. 215 $a1 online resource (71 p.) 225 1 $aSpringerBriefs in Psychology,$x2192-8363 300 $aDescription based upon print version of record. 311 $a3-319-26463-X 320 $aIncludes bibliographical references and index. 327 $aIntroduction -- Why Now the Need for a New Clinical Trial Model for Antidepressants? -- Reconceptualizing Depression and the Componential-Specific Model of Clinical Trials -- Aims and Basic requirements of Clinical Trials: Conventional and Component-Specific Models -- Methods for Measuring the Components and Profile of Drug Actions: The Multivantaged Approach -- The Component-Specific Model Applied in a Clinical Trial: An Example -- Comparing the Component-Specific Model Directly with the Established Diagnosis-Specific Trial -- Prediction and Shortening the Clinical Trial: Further Advantages of the Component-Specific Model -- The Video Clinical Trial and the VIBES Method -- Conclusions. 330 $aThis brief guide takes current clinical trial protocols to task and replaces them with a contemporary framework for improving next-generation antidepressants and their underlying science. Innovative models are based on a nuanced, neurologically-informed understanding of drug mechanisms and the component cognitive, mood, and behavioral aspects of depression. The book reconceptualizes not only the clinical trial process but the clinical concept of depression itself as essential to bringing pharmaceutical research and development up to date, boosting efficiency and effectiveness, finding new molecules, and reducing waste. Case studies and a review of salient depression scales illustrate the potential benefits of such wide-scale change. Included in the coverage: Why now the need for a new clinical trials model for antidepressants? Aims and basic requirements of clinical trials: conventional and component-specific models. Methods for measuring the components and the profile of drug actions: the multivantaged approach. Achieving the ideal clinical trial: an example of the merged componential and established models. Prediction and shortening the clinical trial. The video clinical trial. Clinical Trials of Antidepressants will interest a varied audience, including clinical investigators, academic and pharmaceutical company scientists, clinical trial organizations, psychiatrists, outpatient physicians, psychotherapists, clinical psychologists, psychology graduate students, medical students, and government agencies such as the FDA. 410 0$aSpringerBriefs in Psychology,$x2192-8363 606 $aHealth psychology 606 $aHealth Psychology$3https://scigraph.springernature.com/ontologies/product-market-codes/Y12020 615 0$aHealth psychology. 615 14$aHealth Psychology. 676 $a150 700 $aKatz$b Martin M$4aut$4http://id.loc.gov/vocabulary/relators/aut$0772578 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910254674503321 996 $aClinical Trials of Antidepressants$91577515 997 $aUNINA